Nrf2 activators and inhibitors have demonstrated significant potential in clinical trials across multiple disease areas (e.g., neurodegenerative diseases, chronic kidney disease, cancer), though their specific indications and safety profiles require further investigation and validation. The gene discussed is NFE2L2; the disease is neurodegenerative disease.